PL1713503T3 - Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby - Google Patents

Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby

Info

Publication number
PL1713503T3
PL1713503T3 PL05722948T PL05722948T PL1713503T3 PL 1713503 T3 PL1713503 T3 PL 1713503T3 PL 05722948 T PL05722948 T PL 05722948T PL 05722948 T PL05722948 T PL 05722948T PL 1713503 T3 PL1713503 T3 PL 1713503T3
Authority
PL
Poland
Prior art keywords
inhibition
factor
complement pathway
methods related
alternative complement
Prior art date
Application number
PL05722948T
Other languages
English (en)
Inventor
Vernon Michael Holers
Joshua M Thurman
Christian Taube
Erwin W Gelfand
Gary Steven Gilkeson
Original Assignee
Univ Colorado Regents
Nat Jewish Health
Musc Found For Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/015040 external-priority patent/WO2004103288A2/en
Application filed by Univ Colorado Regents, Nat Jewish Health, Musc Found For Res Dev filed Critical Univ Colorado Regents
Publication of PL1713503T3 publication Critical patent/PL1713503T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05722948T 2004-02-10 2005-02-10 Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby PL1713503T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54359404P 2004-02-10 2004-02-10
PCT/US2004/015040 WO2004103288A2 (en) 2003-05-13 2004-05-13 Method of preventing recurrent miscarriages
US63623904P 2004-12-14 2004-12-14
PCT/US2005/004346 WO2005077417A1 (en) 2004-02-10 2005-02-10 Inhibition of factor b, the alternative complement pathway and methods related thereto
EP05722948.6A EP1713503B1 (en) 2004-02-10 2005-02-10 Inhibition of factor b, the alternative complement pathway and methods related thereto

Publications (1)

Publication Number Publication Date
PL1713503T3 true PL1713503T3 (pl) 2014-02-28

Family

ID=34865159

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05722948T PL1713503T3 (pl) 2004-02-10 2005-02-10 Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby

Country Status (5)

Country Link
EP (2) EP1713503B1 (pl)
AU (1) AU2005212369B2 (pl)
CA (1) CA2561531C (pl)
PL (1) PL1713503T3 (pl)
WO (1) WO2005077417A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1713503T3 (da) 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
US8911733B2 (en) 2005-05-26 2014-12-16 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
PT2044111E (pt) 2006-06-21 2014-11-12 Univ Colorado Regents Abordagem seletiva do fator h do complemento para o tratamento de doenças
SI3028716T1 (sl) 2006-10-10 2021-01-29 Regenesance B.V. Komplementarna inhibicija za izboljšano regeneracijo živcev
CA2680344A1 (en) * 2007-03-14 2008-11-20 Woodruff Emlen Humaneered anti-factor b antibody
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
EP2496259B1 (en) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
KR20140027090A (ko) 2011-01-04 2014-03-06 노파르티스 아게 연령-관련 황반 변성 (amd)의 치료에 유용한 인돌 화합물 또는 그의 유사체
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
ES2712190T3 (es) 2012-06-28 2019-05-09 Novartis Ag Moduladores de la vía del complemento y sus usos
WO2014002053A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
EP2867229B1 (en) 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
EP2867225B1 (en) 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
EP2872503B1 (en) 2012-07-12 2018-06-20 Novartis AG Complement pathway modulators and uses thereof
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
ES2514165B1 (es) * 2013-03-27 2015-09-09 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
US10280423B2 (en) 2014-05-01 2019-05-07 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor B expression
WO2017176651A1 (en) 2016-04-04 2017-10-12 True North Therapeutics, Inc. Anti-complement factor bb antibodies and uses thereof
US11192944B2 (en) * 2017-10-11 2021-12-07 Bioverativ Usa Inc. Methods of inducing complement activity
PH12022552558A1 (en) 2020-04-20 2024-04-22 Genzyme Corp Humanized anti-complement factor bb antibodies and uses thereof
CN121320460B (zh) * 2025-12-16 2026-04-17 山东第二医科大学 构建小鼠肥胖模型的方法及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2043472A1 (en) 1990-06-04 1991-12-05 Mitsutaka Miyabayashi Electrode for secondary battery
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
WO2000021559A2 (en) * 1998-10-09 2000-04-20 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
GB9930659D0 (en) 1999-12-24 2000-02-16 Bio Discovery Ltd Inhibitors of complement activation
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
US20040015040A1 (en) 2002-07-18 2004-01-22 The University Of Cincinnati Flexible, torsionable cardiac framework for heart wall actuation of the natural heart
ES2614274T3 (es) 2002-09-06 2017-05-30 Alexion Pharmaceuticals, Inc. Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages

Also Published As

Publication number Publication date
WO2005077417A1 (en) 2005-08-25
EP1713503A1 (en) 2006-10-25
CA2561531C (en) 2017-05-02
CA2561531A1 (en) 2005-08-25
AU2005212369A1 (en) 2005-08-25
EP2340850A1 (en) 2011-07-06
EP2340850A9 (en) 2012-02-29
AU2005212369B2 (en) 2011-06-23
EP1713503B1 (en) 2013-07-31
EP1713503A4 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
MX286273B (es) Composiciones y metodos para inhibicion de la via jak.
ZA200700351B (en) Compounds, compositions and methods
SG156674A1 (en) Asphaltene inhibition
EP1796489A4 (en) PROTECTIVE SHOES AND METHOD FOR PRODUCING THE SAME
ZA200703884B (en) S-mirtazapine for the treatment of hot flush
IL178888A0 (en) Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
GB0406443D0 (en) Cast-cutter
EP1789055A4 (en) INHIBITORS OF THIAZOLOPYRIDINE KINASE
GB0413608D0 (en) Security aid
SI1713503T1 (sl) Inhibicija faktorja B, alternativna komplementa pot in relevantni postopki
GB2418628B (en) Improved laminates and the manufacture thereof
GB0414760D0 (en) The alternative
GB0514024D0 (en) Padlock
GB0428239D0 (en) Padlock
IL177759A0 (en) Cospeptin, cosmedin and their uses
GB0400537D0 (en) Le beanock/the beanock
GB2420465B (en) The smelly-vision
GB2414745B (en) Euroblock - flood prevention specification
GB0419656D0 (en) The bugcap
GB0409135D0 (en) The gunbi
GB0415527D0 (en) The karkip
GB0416010D0 (en) The levelease
GB0422108D0 (en) The velocoshaft
GB0417973D0 (en) The cat-stand
GB0408727D0 (en) The kwik-drobe